Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Dilated Cardiomyopathy (dcm) Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

4 recruiting trials for Dilated Cardiomyopathy (dcm). Eligibility criteria explained in plain English.

TrialFinderData lists 4 Dilated Cardiomyopathy (dcm) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Research is led by Chinese Academy of Medical Sciences, Fuwai Hospital (1), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1), University Hospital, Essen (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Magnetic Resonance Imaging with Contrast (diagnostic_test, 1 trial), followed by Immunoadsorption, Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
4
Total Trials
4
Recruiting Now
0
Phase 3 Trials
4
Sponsors

Track Dilated Cardiomyopathy (dcm) trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT07354646

The Application of T1 Mapping in Real-World

The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference...

Sponsor: Chinese Academy of Medical Sciences, Fuwai HospitalEnrolling: 20001 location
RECRUITINGNCT06922851

Protein A Immunoadsorption in Dilated Cardiomyopathy (RPIA-DCM)

This study is a multicenter, dual-arm and randomized controlled clinical trial. Sixty patients with dilated cardiomyopathy and positive β1-adrenergic receptor autoantibodies were...

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEnrolling: 601 location
RECRUITINGNCT07359690

Multimodal Analysis of Endomyocardial Biopsies

The goal of this observational study is to pursue a multimodal approach to identify the molecular signatures and immune signalling molecules of various myocardial diseases and...

Sponsor: University Hospital, EssenEnrolling: 2161 location
RECRUITINGNCT06607471

Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients...

Non-ischemic cardiomyopathies (NICM) represent a heterogeneous group of pathologies characterized by absence of obstructive disease of the epicardial coronary vessels and distinct...

Sponsor: Scientific Institute San RaffaeleEnrolling: 150001 location

Frequently Asked Questions

There are currently 4 clinical trials for Dilated Cardiomyopathy (dcm), with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Dilated Cardiomyopathy (dcm), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Dilated Cardiomyopathy (dcm), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.